SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

30 Jul 2024 Evaluate
The company witnessed a 6.18% growth in the revenue at Rs. 10772.70 millions for the quarter ended June 2024 as compared to Rs. 10145.80 millions during the year-ago period.A slim rise of 11.31% was recorded in the Net profit for the quarter ended June 2024 to Rs. 2360.30  millions  From Rs. 2120.40 millions.Operating profit for the quarter ended June 2024 rose to 3442.00 millions as compared to 3083.60 millions of corresponding quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 10772.70 10145.80 6.18 10772.70 10145.80 6.18 39711.20 34112.70 16.41
Other Income 283.70 314.60 -9.82 283.70 314.60 -9.82 1164.80 1327.50 -12.26
PBIDT 3442.00 3083.60 11.62 3442.00 3083.60 11.62 12359.10 8320.30 48.54
Interest 7.20 7.50 -4.00 7.20 7.50 -4.00 68.00 52.30 30.02
PBDT 3434.80 3076.10 11.66 3434.80 3076.10 11.66 12291.10 8268.00 48.66
Depreciation 329.20 322.40 2.11 329.20 322.40 2.11 1321.60 1269.50 4.10
PBT 3105.60 2753.70 12.78 3105.60 2753.70 12.78 10969.50 6998.50 56.74
TAX 745.30 633.30 17.69 745.30 633.30 17.69 2897.10 1411.30 105.28
Deferred Tax 31.10 27.50 13.09 31.10 27.50 13.09 121.30 -29.30 -513.99
PAT 2360.30 2120.40 11.31 2360.30 2120.40 11.31 8072.40 5587.20 44.48
Equity 250.70 252.70 -0.79 250.70 252.70 -0.79 252.70 252.70 0.00
PBIDTM(%) 31.95 30.39 5.13 31.95 30.39 5.13 31.12 24.39 27.60

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×